BR1015-A

DRUG4 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

Essential Hypertension

Phase 1

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions

Not yet recruitingNCT07421388

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2026-04-09End: 2026-06-07Target: 48Updated: 2026-02-19

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions

Not yet recruitingNCT07421414

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2026-04-19End: 2026-06-17Target: 48Updated: 2026-02-19

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions

Not yet recruitingNCT07421375

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2026-04-02End: 2026-05-31Target: 58Updated: 2026-02-19

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions

Not yet recruitingNCT07421401

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2026-04-13End: 2026-06-11Target: 58Updated: 2026-02-19